Kura Oncology Experiences Preclinical Information Supporting Potential for Menin Inhibitor in Diabetes

– Ziftomenib induces insulin manufacturing, improves insulin sensitivity and reduces insulin resistance in preclinical mannequin of kind 2 diabetes –

– Kura advancing a number of, next-generation menin inhibitor drug candidates concentrating on diabetes and different metabolic illnesses –

SAN DIEGO, June 24, 2024 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical firm dedicated to realizing the promise of precision medicines for the remedy of most cancers, at present reported preclinical information supporting the potential therapeutic utility of menin inhibitors within the remedy of diabetes. The brand new findings have been offered this weekend on the American Diabetes Affiliation’s 84^th Scientific Periods in Orlando. Copies of the presentation can be found within the Posters and Displays part on Kura’s web site.

“Regardless of the introduction of a number of choices for the remedy of kind 2 diabetes, a big unmet want exists as a big proportion of sufferers don’t obtain glycemic management,” mentioned Francis Burrows, Ph.D., Senior Vice President, Translational Analysis. “We’re inspired by these preclinical information for ziftomenib in diabetes, which reveal the potential for menin inhibitors to reinforce pancreatic operate and warrant additional analysis in diabetes.”

Sort 2 diabetes is marked by an insufficient variety of practical pancreatic beta cells, which leads to inadequate insulin manufacturing, resulting in hyperglycemia. Ziftomenib demonstrated significant ranges of glycemic management in preclinical in vivo fashions, together with lowered fasting blood glucose ranges and %HbA1C inside 27 days in addition to constant enchancment in each insulin sensitivity and insulin manufacturing. The information present that the results of ziftomenib have been totally maintained following dose discontinuation, suggesting restoration of beta-cell mass. A decline in pancreatic beta-cell operate and/or mass has been outlined as a key contributing issue to illness development in kind 2 diabetes. Notably, in human islet microtissues originating from two donor samples, ziftomenib induced beta-cell proliferation whereas non-beta-cell proliferation was not detectable, demonstrating menin is a viable therapeutic goal for beta-cell mass particular enlargement.

Kura’s first-generation menin inhibitor, ziftomenib, is at present in medical growth as each a monotherapy and together with requirements of look after the remedy of acute leukemias, and it just lately obtained Breakthrough Remedy Designation for the remedy of relapsed/refractory (R/R) NPM1-mutant AML. In the meantime, the Firm continues to make progress towards a number of next-generation menin inhibitor drug candidates, concentrating on diabetes and different metabolic illnesses.

About Sort 2 Diabetes

Diabetes mellitus is characterised by a lowered capability of the physique to provide insulin and/or by a dysregulated response to insulin. Diabetes is grouped into two medical classes in response to the American Diabetes Affiliation (ADA) – kind 1 diabetes and kind 2 diabetes – the latter accounting for 25.3 million recognized sufferers within the U.S. A decline in pancreatic beta-cell operate and/or mass has been outlined as a key contributing issue to illness development in kind 2 diabetes. Lack of practical beta-cell mass is a core element of the pure historical past in kind 2 diabetes (mediated by metabolic dysfunction). Beta cells are discovered within the pancreas and are answerable for the synthesis and secretion of insulin. Insulin is a hormone that helps the physique use glucose for vitality and helps management blood glucose ranges. Though glycemic management is a validated strategy to delaying illness development, many sufferers don’t obtain glycemic management, which may result in vital and doubtlessly deadly renal, cardiac, neurological, and ophthalmic comorbidities.

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical firm dedicated to realizing the promise of precision medicines for the remedy of most cancers. The Firm’s pipeline consists of small molecule drug candidates that concentrate on most cancers signaling pathways. Ziftomenib, a once-daily, oral drug candidate concentrating on the menin-KMT2A protein-protein interplay, has obtained Breakthrough Remedy Designation for the remedy of R/R NPM1-mutant acute myeloid leukemia (AML). Kura has accomplished enrollment in a Section 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML (KOMET-001). The Firm can be conducting a collection of medical trials to judge ziftomenib together with present requirements of care in newly recognized and R/R NPM1-mutant and KMT2A-rearranged AML. Tipifarnib, a potent and selective farnesyl transferase inhibitor (FTI), is at present in a Section 1/2 trial together with alpelisib for sufferers with PIK3CA-dependent head and neck squamous cell carcinoma (KURRENT-HN). Kura can be evaluating KO-2806, a next-generation FTI, in a Section 1 dose-escalation trial as a monotherapy and together with focused therapies (FIT-001). For added data, please go to Kura’s web site at www.kuraoncology.com and observe us on X and LinkedIn.

Ahead-Trying Statements

This information launch comprises sure forward-looking statements that contain dangers and uncertainties that might trigger precise outcomes to be materially totally different from historic outcomes or from any future outcomes expressed or implied by such forward-looking statements. Such forward-looking statements embrace statements relating to, amongst different issues, the efficacy, security and therapeutic potential of ziftomenib, potential advantages of mixing ziftomenib with acceptable requirements of care, and progress and anticipated timing of the ziftomenib program and medical trials. Elements which will trigger precise outcomes to vary materially embrace the danger that compounds that appeared promising in early analysis or medical trials don’t reveal security and/or efficacy in later preclinical research or medical trials, the danger that Kura could not receive approval to market its product candidates, uncertainties related to performing medical trials, regulatory filings, purposes and different interactions with regulatory our bodies, dangers related to reliance on third events to efficiently conduct medical trials, the dangers related to reliance on exterior financing to fulfill capital necessities, and different dangers related to the method of discovering, growing and commercializing medicine which are protected and efficient to be used as human therapeutics, and within the endeavor of constructing a enterprise round such medicine. You might be urged to think about statements that embrace the phrases “could,” “will,” “would,” “may,” “ought to,” “believes,” “estimates,” “initiatives,” “promise,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “designed,” “aim,” or the detrimental of these phrases or different comparable phrases to be unsure and forward-looking. For an extra record and outline of the dangers and uncertainties the Firm faces, please discuss with the Firm’s periodic and different filings with the Securities and Trade Fee, which can be found at www.sec.gov. Such forward-looking statements are present solely as of the date they’re made, and Kura assumes no obligation to replace any forward-looking statements, whether or not because of new data, future occasions or in any other case.

Contacts

Traders:
Pete De Spain
Govt Vice President, Investor Relations &
Company Communications
(858) 500-8833
[email protected] 

Media:
Alexandra Weingarten
Affiliate Director, Company Communications &
Investor Relations
(858) 500-8822
[email protected]